Rua Bioscience (RUA) H2 2026 earnings summary

Executive summary

• FY26 revenue grew 53% to $2.9m, with customer revenue up 71% to $2.6m, reflecting strong commercial progress and execution of an export-led strategy.

• Expanded international presence in Australia, New Zealand, Germany, UK, Czechia, and established Rua genetics in Canada.

• Secured largest export agreement post-year-end in the UK, expected to generate NZ$10m over two years.

Financial highlights

• Revenue from customers increased 71% year-over-year to $2.6m; total revenue up 53% to $2.9m.

• Loss before tax reduced 3% to $3.36m year-over-year; loss before net financing costs reduced 7% to $3.07m.

• Excluding financing costs and one-off inventory impairments, loss narrowed from $3.30m to $3.07m.

Outlook and guidance

• Focus for FY27 is on continued sales growth in established markets and building new revenue streams in Czechia and Canada.

• Sales expected to maintain upward trajectory, supported by investment in new product development.